Anti-clotting drug Xarelto matches standard therapy in a Phase III trial

08/4/2010 | Bloomberg

Bayer's blood thinner Xarelto appeared to work as well as the standard-therapy combination of Sanofi-Aventis' Lovenox and warfarin in preventing deep vein thrombosis during a late-stage study. Patients who received Xarelto were as likely as those given the standard treatment to develop severe and uncontrolled bleeding.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC